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1809period and another patient declined repeat invasive assessment due
to advanced age; therefore, data were available for 8 patients. All
patients had a mean atrioventricular gradient >40 mm Hg and
received CoreValve (Medtronic, Inc., Minneapolis, Minnesota)
implantation by the transfemoral approach. Mean aortic valve
pressure gradients as assessed by transthoracic echocardiography
decreased from 56.3 mm Hg (95% CI: 48.7 to 63.9 mm Hg) to
11.8 mm Hg (95% CI: 8.6 to 14.9 mm Hg; p < 0.01) at 12-month
follow-up.
Using a cutoff value for the CFR ratio of 2.5 (the expected
normal), all patients had impaired CFR prior to TAVI (mean CFR
1.53; 95% CI: 1.27 to 1.8). At follow-up invasive assessment at
a mean of 376 days, there was a signiﬁcant increase in CFR among
the 8 patients (mean absolute increase in CFR at follow-up vs. pre-
TAVI of 0.65; 95 CI: 0.36 to 0.93; p < 0.01) with a mean CFR
of 2.18 (95% CI: 1.88 to 2.47). Although there was a signiﬁcant
change from baseline pre-TAVI measurements to follow-up, there
was no signiﬁcant improvement in CFR immediately post TAVI
(mean change in CFR immediately post-TAVI vs. pre-TAVI of
0.045; 95% CI: 0.4 to 0.49; p ¼ 0.41). These data are also
demonstrated in Figures 1A and 1B, and Figure 1C demonstrates
the raw APV data pre- and post-hyperemia induction at each time
point. There were no adverse events as a result of the invasive CFR
evaluation. The vessel interrogated with the saphenous vein graft
to the left circumﬂex artery in 6 patients (native vessels too diseased
upstream) and the native left circumﬂex artery in 2 patients. Two
cardiologists trained in CFR assessment reviewed the raw traces
and made CFR measurements with the results compared for
interobserver variability. There were no statistically signiﬁcant
differences between the 2 sets of measurements, and both sets of
measurements independently (and when averaged) demonstrated
the same positive primary outcome.
Our data showed that treatment of AS by relieving the me-
chanical obstruction with TAVI led to a signiﬁcant improvement
in CFR at medium-term follow-up. This is the ﬁrst study to
demonstrate this serially using invasive assessments, although it has
been assessed indirectly using noninvasive techniques in 2 nonin-
vasive studies on patients undergoing conventional aortic valve
replacement (3,4).
Limitations of this study include the small sample size. However,
the difﬁculty of performing the current study (serial invasive
measurements sometimes requiring guide catheter cannulation
between CoreValve struts) may explain why it has not been done
previously. However, the magnitude of the change in the principal
variable is consistent with that in other previous noninvasive
studies.
In conclusion, we report that the treatment of severe AS with
TAVI led to a signiﬁcant improvement in coronary ﬂow dynamics
at 12-month follow-up as measured by CFR. This potentially
represents one of the key physiological pathways that is responsible
for symptomatic and prognostic improvement of patients with AS
who are treated with TAVI.Anthony C. Camuglia, MBBS (Hons)
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Versus End-Stage
Liver Disease
Two Different Entities
Kim et al. (1) have recently reported that the assessment of liver
function may be a useful tool in the prediction of prognosis in
patients with chronic heart failure (HF). Liver dysfunction is a
frequent ﬁnding in HF, especially if signs of accompanying right-
sided HF are present (2). Indeed, impairment of hepatic function
is typically caused by venous congestion as a result of backward
HF (2). Congestion of the liver and intestinal wall may promote
worse outcomes due to increased intestinal translocation and
decreased hepatic clearance of bacterial endotoxin resulting in
prognostically important activation of systemic inﬂammation (3,4).
Kim et al. (1) have used the MELD (Model of End Stage Liver
Disease) scoring system to assess the liver function in patients with
HF. The components of the MELD score, total bilirubin, serum
creatinine, and the international normalized ratio reﬂect, however,
not only liver dysfunction but also the prognostically relevant renal
failure and atrial ﬁbrillation (5–7); the last if patients are adequately
treated with oral anticoagulants. The use of the MELD score in
patients with chronic HF should, in our opinion, be understood as
assessment of all 3 comorbidities.
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1810The use of total bilirubin as a component of the MELD score is
comprehensible if applying the score to patients with liver cirrhosis,
as the complex distortion of hepatic lobule results in elevation of
both indirect and direct bilirubin. However, liver cirrhosis as an
end-stage organ failure is a rare ﬁnding in patients with HF
nowadays (8). The underlying mechanism responsible for abnormal
liver function tests in patients with HF is primarily liver congestion
due to backward right HF. This results predominantly in mild
elevation of cholestatic markers (2). Thus, direct bilirubin is
probably a more speciﬁc indicator of liver dysfunction in patients
with chronic HF than total bilirubin is, especially as total bilirubin
might be elevated due to other reasons than chronic HF. Therefore,
we suggest modifying the MELD score for HF patients by using
direct bilirubin instead of total bilirubin.
As the investigators themselves state, there cannot be established
any causality between a higher MELD score and mortality and/
or need for cardiac transplantation. Beyond the reported association
between markers of right heart function and the MELD score, it
would be helpful to provide information about the medication of
patients with a higher MELD score. What if the score reﬂected
sicker patients with more medication and a variety of subsequent
drug-liver interactions and only to a lesser extent the suggested
congestion due to HF?
In accordance with Eisen (9), we think that it remains to be
elucidated whether optimization of medical therapy can lower the
MELD score. Especially interventions targeting splanchnic
congestion (e.g., intensiﬁed diuretic therapy) are eagerly awaited and
should be evaluated with regard to the stability of the MELD score.*Miroslava Valentova, MD
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End-Stage Liver Disease
Two Different Entities
We thank Dr. Valentova and colleagues for their insightful
comments on our recent study (1) of liver function abnormalities
characterized by various MELD (Model of End Stage Liver
Disease) scoring systems in patients evaluated for heart trans-
plantation (HTx). On the basis of our analysis, utilization of
MELD scoring systems may improve our risk prediction on the
basis of a composite evaluation of end-organ dysfunction including
liver and renal functional abnormalities. Of note, the use of the
standard MELD score is limited to patients not on oral anti-
coagulation due to the impact of vitamin K antagonists on the
international normalized ratio (INR), which is an essential
component of the standard MELD score. For that reason, we
analyzed both patients on and off oral anticoagulants separately
and included the modiﬁed MELD-XI score, which allows char-
acterization of patients on vitamin K antagonists.
Dr. Valentova and colleagues also state that in patients with
liver cirrhosis, the use of total bilirubin is most appropriate and
that liver cirrhosis is a rare ﬁnding in patients with HF. This does
not reﬂect our experience, as the degree of liver cirrhosis is a
frequent concern in our population of patients evaluated for HTx;
in particular, in patients with longstanding right and biventricular
heart failure, patients on left ventricular assist device support and
patients with congenital heart disease after, for example, Fontan
repair. At our center, we performed liver biopsies in more than 5%
of all transplant candidates evaluated between January 1, 2000
and April 1, 2013 due to the suspicion of structural liver damage
such as liver ﬁbrosis secondary to congestive hepatopathy, previous
hepatitis or irreversible liver function abnormalities, and concom-
itant imaging abnormalities. Unfortunately, our current analysis
focused on the utilization of MELD scores that included only total
bilirubin, and we did not include direct bilirubin into our analysis
(1). It would be interesting, however, to study this parameter in a
subsequent analysis. Nevertheless, the impact of bilirubin and its
speciﬁc statistical weight within the composite MELD scores has
only been established for total bilirubin, and it will require ad-
justments if direct bilirubin will be used instead of total bilirubin.
We agree with Dr. Valentova and colleagues that elevated
MELD scores might reﬂect more severe comorbidities and
more advanced HF. However, in our cohort, we did not detect
